<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR41">
 <label>41.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Heiss</surname>
    <given-names>MM</given-names>
   </name>
   <name>
    <surname>Murawa</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Koralewski</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Kutarska</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Kolesnik</surname>
    <given-names>OO</given-names>
   </name>
   <name>
    <surname>Ivanchenko</surname>
    <given-names>VV</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial</article-title>
  <source>Int J Cancer</source>
  <year>2010</year>
  <volume>127</volume>
  <fpage>2209</fpage>
  <lpage>2221</lpage>
  <pub-id pub-id-type="doi">10.1002/ijc.25423</pub-id>
  <?supplied-pmid 20473913?>
  <pub-id pub-id-type="pmid">20473913</pub-id>
 </element-citation>
</ref>
